Jaguar Health, Inc. (JAGX) stock forecast & analysis
17.69
NasdaqCM · USD
Down: -16.77, -48.7%
1 analysis
- Open
- 15.39
- Previous close
- 34.46
- Day range
- 14.64 – 19.00
- 52-week range
- 2.35 – 1,281.00
- Volume (shares)
- 4.75M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 520.09K
- P/E ratio
- 0.00
- Dividend yield
- Not available
- Beta
- -0.06
- Market cap
- 9.20M
Market Scanner’s AI analysis of Jaguar Health, Inc. (JAGX), updated September 2026: JAGX's recent reports detailed a sharp bearish technical trend alongside FDA fee waivers and a reverse stock split.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Jaguar Health, Inc. (JAGX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
JAGX's recent reports detailed a sharp bearish technical trend alongside FDA fee waivers and a reverse stock split.
Recent analyses for JAGX covered a strong bearish technical trend, evidenced by significant declines across multiple moving averages and momentum indicators. The company's financial fundamentals indicated short-term liquidity challenges and a substantial year-over-year revenue decrease. However, recent news highlighted positive developments including FDA fee waivers and a reverse stock split, which contributed to a notable surge in share price.
JAGX news & sentiment
Market sentiment for JAGX saw a significant positive shift following news of FDA fee waivers and a reverse stock split, leading to a notable surge in share price and making it a midday gainer. Social media discussion was not covered in the provided notes.
JAGX technical picture
JAGX's technical indicators showed a strong bearish trend, with the price trading significantly below its 50-day and 200-day SMAs. Momentum readings from the RSI, MFI, and MACD confirmed extreme selling pressure and bearish momentum, while the price was also below the lower Bollinger Band.
Fundamentals
The company's revenue has seen a significant year-over-year decline, with substantial net losses reported across recent annual and quarterly periods. Financials indicate potential short-term liquidity challenges, as evidenced by a low current and quick ratio, alongside a notable amount of total debt relative to its market capitalization.
Factors discussed — upside
- FDA fee waivers received on September 22nd
- Company announced a reverse stock split
- Stock was a top midday gainer on September 22nd
- Experienced a more than 10% premarket surge on September 23rd
Factors discussed — risks
- Strong bearish technical trend indicated by multiple indicators
- Price significantly below 50-day and 200-day SMAs
- RSI and MFI below oversold thresholds
- Negative and trending downwards MACD
- Current ratio of 0.739 and quick ratio of 0.168 indicating liquidity challenges
- Technical indicators
- Financial fundamentals
- Regulatory developments
- Corporate actions
Summary updated .
JAGX technical indicators
Common technical indicators for JAGX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 12.90 | Price above |
| 10-day exponential moving average | 6.95 | Price above |
| Relative strength index (14-day) | 68.00 | Neutral |
| MACD line (12/26/9) | -2.3408 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -0.81 – 17.27 | Price above the upper band |
Analyses
Recent JAGX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Jaguar Health, Inc.?
- The bull case for JAGX centered on recent positive regulatory news, including FDA fee waivers, and corporate actions like a reverse stock split. These developments were accompanied by notable share price surges and the stock being recognized as a top midday gainer.
- What are the risks for Jaguar Health, Inc.?
- The bear case for JAGX highlighted a strong bearish technical trend with prices significantly below key moving averages and indicators showing extreme selling pressure. Financially, the company faces liquidity challenges due to a low current ratio and quick ratio, alongside significant year-over-year revenue declines and consistent net losses.
- Is Jaguar Health, Inc. bullish or bearish?
- Recent AI analyses of Jaguar Health, Inc. examined factors on both sides. Discussed upside: The bull case for JAGX centered on recent positive regulatory news, including FDA fee waivers, and corporate actions like a reverse stock split. These developments were accompanied by notable share price surges and the stock being recognized as a top midday gainer. Discussed risks: The bear case for JAGX highlighted a strong bearish technical trend with prices significantly below key moving averages and indicators showing extreme selling pressure. Financially, the company faces liquidity challenges due to a low current ratio and quick ratio, alongside significant year-over-year revenue declines and consistent net losses. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Jaguar Health, Inc.?
- Market sentiment for JAGX saw a significant positive shift following news of FDA fee waivers and a reverse stock split, leading to a notable surge in share price and making it a midday gainer. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Jaguar Health, Inc.?
- Every analysis of Jaguar Health, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh JAGX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.